Conmed (CNMD) EBITDA (2010 - 2026)

Conmed's EBITDA history runs 17 years deep, the most recent figure standing at $25.4 million for Q1 2026.

• Quarterly EBITDA rose 59.26% year-over-year to $25.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $112.1 million (down 38.17% YoY) and the FY2025 annual result came in at $102.6 million, down 48.77% from the prior year.
• EBITDA was $25.4 million for Q1 2026 at Conmed, down from $36.6 million in the prior quarter.
• Across five years, EBITDA topped out at $65.7 million in Q3 2024 and bottomed at -$1.1 million in Q4 2022.
• A 5-year average of $30.5 million and a median of $27.4 million in 2023 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA tumbled 102.94% — and 2023, when it surged 4683.29%.
• Conmed's EBITDA stood at -$1.1 million in 2022, then jumped by 4683.29% to $50.2 million in 2023, then gained by 4.61% to $52.5 million in 2024, then slumped by 30.24% to $36.6 million in 2025, then slumped by 30.61% to $25.4 million in 2026.
• Business Quant data shows CNMD's EBITDA at $25.4 million in Q1 2026, $36.6 million in Q4 2025, and $11.9 million in Q3 2025.